neurons in the substantia nigra pars compacta, is an age-related neurodegenerative disorder and can result in significant disability and morbidity. In the early stage of the disease most symptoms can be well controlled by L-DOPA, but with its continuous usage multiple motor side effects develop, which include the end-ofdose 'wearing off' phenomenon, Levodopa-induced-dyskinesia(LID), "on-off" fluctuation, involuntary movements, neuropsychiatric phenomena, and sensory symptoms, etc. 1-4 . Since medical therapy fails to provide good, longlasting relief of symptoms, interest in the surgical treatment of PD has been rekindled.
Introduction
Parkinson's disease, which is characterized by a clinical triad of akinesia, rigidity and tremor marked by degeneration of dopaminergic since the 1980s. In this paper, surgical procedures in the post-levodopa era are critically reviewed.
Neurophysiology relevant to treatment of Parkinson's disease
The rebirth of PD surgery during the past decade has been facilitated by advances in our understanding of the basic anatomy and physiology of the basal ganglia and motor systems, as well as the pathophysiology of PD. In the parkinsonian state, the natural balance within the motor loop is lost owing to the depletion of dopamine in the striatum. Both the direct and indirect pathways operate through the GPi/SNr output nuclei and their influence is inhibitory on the thalamus.
The loss of dopamine leads to increased activity in the output nuclei, which in turn leads to underactivation of motor cortical areas, resulting in a reduction in movement observed in patients as the hypokinetic symptoms of PD (rigidity and bradykinesia) 3,4,8,9 . This model of basal ganglia activity accounts generally for the clinical effects of pallidal interventions, such as pallidotomy, that are aimed at reducing the abnormal GPi activity. Attenuation of GPi overactivity restores more normal thalamocortical and brainstem activity and alleviates hypokinetic symptoms and tremor. The model also predicts that therapies directed at reducing the overactivity of STN might have even greater clinical effects than therapy directed at GPi because STN intervention restores more normal activity in both GPi and SNr, whereas therapy directed toward GPi does not correct abnormal activity in SNr 3, 4, 8, 9 . This prediction has been borne out by preliminary clinical studies.
Ablative surgery
Before the introduction of levodopa, the treatment of severe PD by selective destruction of basal ganglia was the only option available. There is no comprehensive theory behind this approach; it was discovered by chance, and targeting of specific areas of the brain is still mostly empirical 10 . Although ablative treatments, as well as DBS, are not curative, their success rate in improving PD symptoms is usually reported in the range of 40 to 90%, depending on specific treatment and observation period.
Thalamotomy
In the thalamus, the ventral intermediate nucleus is the primary region targeted for the relief of the tremor. Lesions in the ventral intermediate nucleus are highly effective in alleviating parkinsonian tremor in more than 85% of patients 11 . If extended anteriorly to include the ventral oralis posterior, and possibly portions of the ventral oralis anterior, rigidity and dopainduced dyskinesia also improve 12 .
Thalamotomy generally does not improve bradykinesia or akinesia and may exacerbate speech and gait disorders in some patients 13, 14 .
In addition, bilateral thalamotomy can relieve bilateral parkinsonian disease, but results in a prohibitively high rate of cognitive and speech problems 13, 15 , which prevent the use of this procedure for most patients with Parkinson's disease. Given the success of pallidotomy and DBS of the subthalamic nucleus and internal globus pallidus in improving all the cardinal motor symptoms of Parkinson's disease and the lower incidence of side-effects with DBS, thalamotomy is generally not recommended.
Pallidotomy
Pallidotomy, a widely accepted surgical treatment for PD, improves tremor, rigidity, and bradykinesia in most patients [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] . As measured by a standardized assessment tool, the Unified Parkinson's Disease Rating Scale (UPDRS) 26 , pallidotomy improves motor scores (measured while patients are off medications) from 14% 22 to 69% 17 . Levodopa-induced dyskinesias, which occur while patients are on medications, improve significantly with reductions (based on the UPDRS dyskinesia scale) ranging from 49% 19 to 73% 24 . UPDRS Activities of Daily Living scores improve 30-50% 16, 20 . Most clinical benefit from pallidotomy is seen on the side of the body contralateral to the procedure. Ipsilateral and axial (e.g. postural instability) symptoms can improve, but these improvements are not maintained consistently past one year 16, 18, 20, 27, 28 . Medication requirements generally do not change after pallidotomy 16, 20, 27, 28 .
Serious complications from unilateral pallidotomy are not common (generally in the range of 2-8%) 9, 27, 29 . Complications that do occur tend to be mild and are frequently transient. Complications include visual impairment 7, 9, 30 , facial paresis, hemiparesis 7, 9, 29, 31 , and changes in speech, voice volume and memory. Changes in neuropsychological status have been reported but are not a consistent finding 16, 28, [32] [33] [34] .
Although the primary clinical benefit of pallidotomy is contralateral to the surgical site, some patients improve sufficiently after unilateral pallidotomy to make bilateral pallidotomy not necessary. For others, bilateral pallidotomy can provide improvement in symptoms beyond that provided by unilateral pallidotomy 27, [35] [36] [37] . Most patients undergoing bilateral pallidotomy are pleased with the outcome, but the risk of complications is substantially greater when the procedure is performed bilaterally 33, 38, 39 . In particular, bilateral pallidotomy may cause dysfunction of speech (hypophonia and dysarthria), swallowing (drooling) 33, 38 , balance and memory in as many as 50% of patients. Concerned about the incidence of complications following bilateral pallidotomy, some experts recommend against the procedure except for limited indications 9, 27, 38, 40 . Bilateral DBS (or contralateral DBS for patients who have undergone a unilateral pallidotomy) may provide a safe alternative to bilateral pallidotomy.
Subthalamotomy
Whereas many studies reported that pallidotomy or thalamotomy can effectively improve parkinsonian symptoms, few research groups have carried out subthalamic lesions studies. Because of the intractable hemiballism associated with lesions in the subthalamic nuclei, researchers were reluctant to explore this therapeutic approach.
After DBS of the subthalamic nucleus was successfully applied to the treatment of Parkinson's disease, a series of subthalamotomy case reports, as a cheaper alternative to DBS, have been reported in the past decade.
A study of up to 21 patients with unilateral subthalamic lesions has showed that UPDRS motor score in the 'off-medicine' was improved by 15-50% at two year follow-up [41] [42] [43] . With bilateral subthalamotomy, Alvarez and colleagues reported 18 patients with 58% improvement in the off-medicine UPDRS motor score and a 63% improvement in the on-medicine score at two years 44 . Up to half of the patients developed Huntington's chorea, but in most cases the symptom was mild, lasting from a few hours to five days 41, 42 .
One group reported that one patient developed refractory chorea eventually leading to fatal aspiration pneumonia. However, others have found that postoperative chorea can be easily ameliorated by an ipsilateral pallidotomy 41 or thalamotomy of the ventral intermediate nucleus and ventral oralis posterior 45 .
These promising results suggested that compared with pallidotomy or DBS of the subthalamic nucleus or GPi, subthalamotomy can also be safely carried out and have beneficial effects. Although the hazard of hemichorea exists, its incidence is not as high as previously thought. Thus far, side-effects of speech and cognitive functions resulting from bilateral subthalamotomy seem to be fewer those that of bilateral pallidotomy or thalamotomy, and at the same time, drug intake can be reduced.
Deep brain stimulation, DBS
Benabid et Al. 46 were the first to propose that chronic high-frequency deep brain stimulation (DBS) could simulate the effects of a lesion and avoid the need to make a destructive brain lesion and might be a useful treatment in PD. They proposed that chronic stimulation could be accomplished by connecting an electrode implanted into a specific brain target to a programmable stimulator. Optimal stimulation parameters could be determined by varying the electrode configuration (each electrode has four individual contact sites), and the stimulation voltage, pulse width, and frequency. DBS had previously been employed as a therapy for intractable pain and dyskinesia 47, 48 and was shown to be well tolerated. The principal advantage of DBS is its capacity to provide functional benefits without the necessity of creating a destructive brain lesion, thereby avoiding adverse events caused by damage to neighboring structures. This is a particular advantage if bilateral procedures need to be performed. It also permits targeting regions in the brain that one might be unwilling to lesion such as the subthalamic nucleus (STN) or the GPi bilaterally. Other advantages of DBS include the potential to adjust the stimulator at any time after surgery in order to maximize benefits and minimize adversity.
Further, the procedure does not mitigate against the introduction of a more effective therapy in the future that requires the integrity of the basal ganglia system.
Ventralis intermedius nucleus, VIM
DBS for PD was first tested in the VIM nucleus of the thalamus in patients with tremor predominant symptoms 49, 50 . DBS of the VIM nucleus was initially investigated in patients who had previously undergone a thalamotomy in order to diminish the risks associated with bilateral thalamic lesions 51 . DBS of the VIM has now been shown to dramatically ameliorate contralateral tremor 52 , and these results have been confirmed in a double-blind crossover study 53 . A randomized trial demonstrated that DBS-VIM provides benefits comparable to thalamotomy with fewer adverse events 54 . Tremor reduction is generally observed one to three seconds after the stimulator is turned on and the effect is lost within seconds after the stimulator is turned off. Benefits have been observed to persist for as long as ten years and benefit continues to be lost when stimulation is discontinued.
Unfortunately, the benefits of DBS-VIM do not extend to the more disabling parkinsonian features such as rigidity, bradykinesia and gait dysfunction. For this reason, interest has shifted to stimulation of the GPi and subthalamic nucleus (STN) as primary targets in PD based on preclinical and clinical evidence indicated that stimulation of these targets has a greater possibility of improving the entire constellation of parkinsonian motor dysfunction.
The most common complication of DBS-VIM for Parkinson's disease tremor is worsening dysarthria, which occurs in about 20% of patients. Tremor is more common with bilateral simulation and can be decreased with adjustment of stimulation parameters 49 . This rate of complications is lower than the 30%~50% incidence of speech difficulties in patients with bilateral thalamotomy. The major advantage to Vim stimulation is that unlike thalamotomy, the side-effects resulting from stimulation are reversible 55, 56 . However, the lack of reliable efficacy on other motor symptoms has limited the use of DBS-VIM for Parkinson's disease.
Globus Pallidus Internus, GPi
The only large, prospective, double-blind study of bilateral DBS of the internal globus pallidus was a multicentre study that reported a 37% improvement in "off-medicine" UPDRS motor subscore in 38 patients at three months 57 .
Although this study enrolled patients for both bilateral internal-globus-pallidus DBS and subthalamic-nucleus DBS, patients had not been randomized to stimulation site. This study was designed to show safety and efficacy and not to compare the two modalities.
The only randomised, blinded comparison of DBS of these two targets was small (ten patients) and did not show a significant difference between the sites: internal-globus-pallidus DBS caused a 39% improvement at one year in four patients 58 . Other bilateral internal globus pallidus case analyses showed consistently positive results with improvement in "off" motor subscore up to 56%. Studies of bilateral stimulation of the internal globus pallidus in patients of followed up for two years or longer have shown stable benefit. The results of one study of the bilateral globus pallidus DBS in 11 patients followed up for up to five years showed that dyskinesias remained significantly reduced until the last assessment, but initial improvement of "off"-period motor symptoms and fluctuations was not sustained and gradually declined 59 . Whether or not this study is representative of the long-term effect of DBS of the internal globus pallidus requires further study in more patients.In contrast to thalamotomy or Vim DBS, GPi DBS has reliably alleviated all cardinal motor symptoms of Parkinson's disease including akinesia, brandkinesia, rigidity, tremor and gait 39, 57, 58, [60] [61] [62] [63] [64] [65] [66] [67] . DBS of GPi improves "off" dystonia 68, 69 and, like pallidotomy, has a strong, direct, suppressing effect on levodopainduced dyskinesias 39, 58, 65, [70] [71] [72] . Internal-globuspallidus stimulation also improves postural instability and gait 60, 63, [73] [74] [75] . These changes were more noticeable in patients with bilateral rather than unilateral stimulation. In addition, "on" time is substantially increased: the 38 patients in the DBS for Parkinson's disease improved their percentage of "on" time from 28% to 64% 57 .
Complications directly related to GPi stimulation are moderate, and are generally reduced or eliminated with adjustment of stimulation parameters. There are few reports of adverse effects on speech, mood and cognition, and case reports of mania 76 , apathy 77 and mild decline in lexical verbal memory 39 . Of the studies of detailed neuropsychological testing, most have shown that no overall change, with minimum subclinical changes occurring in some patients 78, 79 .
Subthalamus Nucleus, STN
DBS of the subthalamic nucleus, like that of the internal globus pallidus, improves all cardinal motor symptoms of Parkinson's disease. No randomised, blind clinical experiments have showed the superiority of one method over the other. However, DBS of the subthalamic nucleus is generally preferred and is done more than that of the internal globus pallidus. Study of DBS for Parkinson's disease showed that in "off-medicine" UPDRS motor subscore, improvement in bilateral stimulation of subthalamic nucleus is slightly greater than that of bilateral stimulation of the internal globus pallidus, 49% and 37% respectively 57 . But this study was not blinded and did not randomly assign patients by sites. As such, it is difficult to compare the results from the two sites. These results and those of other studies of stimulations of the subthalamic nucleus have been consistently robust with most studies showing 45-55% improvement and some showing as high as 60-70% improvement in "off" medicine motor subscore 57, 58, [60] [61] [62] [80] [81] [82] . Study of 42 patients followed up for five years showed that improvement seems to be stable with continued efficacy and a 54% improvement in "off" motor score 80 . "On" time is also significantly increased from baseline 27% to 74% at three months 57 . Bilateral stimulation of STN may produce dramatic beneficial effects on midline symptoms such as gait, posture and balance 60 .
Although intake of antiparkinsonian drugs can be substantially decreased with subthalamus DBS, drug adjustment may be more difficult than that with stimulation of the internal globus pallidus 81, [83] [84] [85] . Some centres substantially decrease drugs after surgery; there are now reports that patients do not tolerate this and experience significant mood side-effects. If done properly -titrating stimulation variables up as treatment is reduced -patients tolerate these adjustments well and continue to show significant improvement in postoperative motor scores 81 .
In addition to simulation-induced dyskinesia, there are more reports of mood, behavioural, and cognitive side-effects associated with subthalamic-nucleus stimulation than with internal-globus-pallidus stimulation. This may be due to higher subthalamic nucleus implantation rates and therefore there are more reports of side-effects. However, the unique anatomic characteristics also cause this effect -its small size necessitates implantation of a DBS lead in regions near non-motor portions, and its vicinity to important neighbouring structures. Inadvertent current spread into non-motor portions of the STN and adjacent structures may affect cognition and behaviour by modulation of frontal and limbic function. DBS of the subthalamic nucleus may worsen the cognitive function of some patients, especially older patients 86 and those with preoperative cognitive decline 87 . By contrast, young and non-demented patients show no significant cognitive change 88 . Limbic circuits have strong connections with the medial subthalamic nucleus, and not surprisingly, stimulation can cause apathy, depression or mania 62, 86, [89] [90] [91] [92] [93] . Depression and apathy may also occur because of a sudden reduction of levodopa and hence patients may show an improvement with increasing dopaminergic treatment 94 . DBS of the subthalamic nucleus, especially with stimulation in the left side, also produces depression 90, 95 ; whereas right side stimulation can develop mirthful laughter 96 . Most side-effects associated with stimulation of the STN can be reduced with adjustment of stimulation parameters. However, mood and cognition changes can be more occult, and may not be immediately noted.
Cell Transplantation
The methods described above so far aim at altering the physical manifestations of the disease without affecting its natural history. Cell transplantation, on the other hand, is an alternative approach to treat PD by replacing the dopaminergic neurones within the basal ganglion, and thereby reversing or compensating for the ongoing neurodegenerative process. Although initial attempts to replace lost neurons in PD patients by transplantation date back almost 20 years, this approach is still in an experimental, preliminary stage. The first problem to be resolved is the origin of the material to be transplanted. Three major sources of dopamine-producing cells are being considered.
Human Fetal Neural Cells
One type of transplantation is dopamineproducing neurons or their precursors from human fetal tissue, most notably human embryonic dopaminergic nigral grafts.
There have been sporadic case reports of fetal neural transplantation for Parkinson's disease over the years with Freed and colleagues publishing the first placebo-controlled trial 97 . Although uptake of fluorodopa increased on PET scan, clinical improvement did not always correlate and was more profound in younger patients. In addition, 15% of the patients demonstrated dyskinesias similar to those seen on levodopa.
Subsequent discussions have arisen regarding the severity of dyskinesias seen after neural transplantation. Hagell et Al 98 reviewed 14 patients who received fetal transplantation with up to 11 years of follow-up. They found that eight of these patients had mild dyskinesias that caused no distress to the patient. Of the remaining six patients with more severe dyskinesias, there was only one patient with a clinical therapeutic problem. However, these patients are difficult to compare with one another because they underwent transplantation under different conditions. Ma et Al 99 , in a study with PET using (18F) fluorodopa, concluded that uptake was increased significantly in patients with dyskinesias after transplants as compared with those without dyskinesias, and these increases were predominantly in two zones within the putamen. These findings suggest that more targeted transplantation is necessary and that there exists a therapeutic window in which increasing dopamine with transplantation does not cause dyskinesia. Despite these issues, the authors concluded that this is not a sufficient reason to discontinue studies using fetal neural transplantation. Double grafts in the putamen and substantia nigra are reportedly safe and have shown improvement in UPDRS in three patients 100 .
XenoTransplantation
The difficulties with using human foetal tissue have led to the search for alternative sources of tissue, including porcine neural cells. However, there are fundamental problems with using such tissue, including risks of infection and issues of immune rejection 101, 102 . Neither of these problems has been resolved experimentally and so it is not surprising that the clinical results to date have been largely disappointing, with some clinical improvement but no significant dopaminergic cell survival at post-mortem or on 18 F-dopa PET scans [103] [104] [105] .
Stem Cells
The question of whether fetal transplantation could provide adequate numbers of dopaminergic cells has led researchers to look to embryonic stem cells for the treatment of Parkinson's disease. Although animal studies have shown that survival of these cells is four times higher than that of fetal cells, only 22% of grafted cells survived and only a small fraction of those expressed dopamine 106 . Kim and coworkers 107 expressed the Nurr 1 protein in embryonic stem cells prior to transplanting them into rats. Nurr 1 plays a role in differentiation of mid-brain precursors into dopamineproducing neurons, and may influence cell survival. The animals exhibited improvement in parkinsonian symptoms and in electophysiologic properties 108 . Other methods of inducing dopamine production from stem cells have been used with less or similar success 106 . More recent studies suggest that stem cells can potentially develop dopamine phenotypes 109, 110 .
Embryonic stem cells can also be engineered to deliver other drugs and growth factors. Temporary increases in survival of co-grafted primary dopamine neurons were seen with stem cells engineered with GDNF 111 . GDNF expressing neural stem cells still differentiated into atrocytes, neurons, or oligodendrocytes. Even after differentiating, they continued to express GDNF. They also prevented degeneration of dopamine neurons after 6-hydroxydopamine injections and reduced apomorphine-and amphetamine-induced turning behavior when compared with controls 112 . Their advantage over viral delivery is that the neurons are not genetically changed and there is no chance of mutagenesis 106 . Akerud et Al 113 over-expressed persephin, a member of the GDNF family, in neural stem cells. They demonstrated in vivo findings similar to those with GDNF when injected into mouse striatum.
Stem cells currently are an extremely attractive but controversial therapy. Social issues continue to influence the pace of scientific progress and probably will limit the supply of available tissue if renewable sources of functional cells are not found. Several scientific hurdles also remain. Embryonic stem cells may not be immunologically compatible with most patients, and they could cause teratomas if tight control over differentiation and cell proliferation is not achieved. Our understanding of the rules and limits to integration of differentiated cells into neural circuits is also in its infancy. A complete understanding will be necessary if we are to realize fully the potential of stem cells. Nonetheless, the active interest and substantial recent progress in this area sustain the enthusiastic hope that this approach could eventually achieve the ultimate goal of repairing the damaged brain.
Growth Factor and Gene Therapy
In addition, other researchers propose the use of neural trophic factors for the treatment of Parkinson's disease. Neural trophic factors have been used as a method of promoting the restoration and maintenance of degenerating dopaminergic cells 114, 115 . A large, multicentre, double-blind placebo controlled trial of intraventricular infusion of gial-cell-derived neurotrophic factor showed no benefit at eight months 115 . After these disappointing results, investigators proposed direct infusion of gialcell-derived neurotrophic factor into putamen. The open-label, phase I clinical study showed a 39% improvement in the "off" UPDRS motor score in patients receiving up to 43.2. μg/putamen/day of gail-cell-derived neurotrophic factor 114 . Gene therapy has been tried to introduce GDNF to basal ganglia for the treatment of Parkinsonian motor symptoms. In an MPTP monkey model of Parkinson's disease, production of gail-cell-derived neurotrophic factor in striatum and substantia nigra was increased and associated with improvement of parkinsonian symptoms 116 . Whether the use of gene therapy of infusion to introduce trophic factors into the nervous system will prove to be effective is unknown.
Another method using gene therapy has been started to deliver glutamic acid decarboxylase into subthalamic-nucleus glutamatergic cells with the aim of promoting GABA production in these cells, thus changing the action of these neurons from excitatory to inhibitory 117 and reducing the excessive output from the subthalamic nucleus proposed to underline the development of many of the motor signs of Parkinson's disease.
Conclusions
For a select patient population, stereotactic ablation and DBS have significant roles to play in the treatment of Parkinson's disease. The use of thalamotomy and thalamic DBS should be limited to those patients with mainly drug resistant tremor. Stimulation of the globus pallidus has been shown to be of benefit, but it has been largely supplanted by bilateral STN DBS. In patients who respond to L-dopa but have intolerable adverse effects, STN DBS can decrease medication dosage and improve function status. Gene therapy, direct drug infusion, and fetal cell transplantation have all been or currently are in clinical trails, so that scientifically advanced treatments are no longer exclusively theoretical.
Continued developments in these areas and in stem cell research will probably alter surgical practice for Parkinson's disease patients within the foreseeable future.
